Authors [Ref]

T1D Subjects

Observations

 

Bradshaw et al., [33]

 

Recent and long-term patients

 

Increased frequency of IL-17 secreting cells in long-term diabetic patients, increased production of IL-1β and IFN-γ by monocytes driving Th17 profile.

Marwaha et al., [34]

New-onset patients

Increased proportion of both CD4+ and CD8+ T cells that produce IL-17.

Honkanen et al., [35]

Diabetic children

Peripheral T cells: Increased IL-17 secretion; increased levels of IL-17A, RORC2, IL-22 transcripts; IL-17 increased inflammatory and apoptotic responses in human islets cells.

Han et al., [36]

At-risk, new-onset
and long-term patients

Increased IL-17 mRNA levels in new-onset diabetic patients when compared with at-risk, long-term and healthy individuals.

Arif et al., [37]

New-onset patients

Presence of circulating beta cells-specific Th17 cells, increased IL-17A expression in pancreatic tissue, IL-17 plus IL-1β, IFN-γ and TNF-α promoted beta cell apoptosis.

Ferraro et al., [38]

Long-term patients

Increased numbers of Th17 cells in pancreatic lymph nodes, increased IL-17 production after islet-antigen stimulation, decreased numbers and function of Treg cells, Treg/Th17 cell ratio was 4-5 times lower than health group.

Table 1: Investigations about the role of Th17 immune response in patients with T1D.